This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Finance & Accounting for Bioscience Companies East
Delivered as a Hybrid Event
September 19-20, 2022Boston, MA

Ryan Starkes, CPA
Partner at Centri Business Consulting


Ryan is a Partner for the firm’s New York Metro-based practice and has more than 25 years of public and private accounting experience. Throughout his career, Ryan has worked with public, privately held and private equity portfolio entities, ranging from pre-IPO entrepreneurial startups to large public multinational corporations aiding, collectively from an audit, consultative and internal perspective, while supporting a multitude of financial accounting advisory, financial reporting and internal control issues and transactions.

As an audit partner at BDO USA, LLP for twelve years (2005-2018), Ryan also served as the National Life Sciences Practice Leader for BDO USA, LLP, and previously as one of its Practice Leaders for the firm’s Technology & Life Sciences Industry Group. Ryan’s prior experience also includes leading the SEC Reporting Group at a Fortune 50 pharmaceutical company (2002-2005). Prior to joining Centri, Ryan was a Partner at a technical accounting and consulting firm that provides financial accounting advisory and financial reporting services to private and public companies and pre-IPO companies.

Ryan earned a BBA in Accounting from Hofstra University in 1992 and is a Certified Public Accountant. He is a member of both the AICPA, New York and New Jersey State Society of Certified Public Accountants. During his time at BDO, Ryan authored many of the life sciences industry publications and was a frequent presenter/moderator/trainer at various internal and external events.

Ryan Starkes, CPA's Network

Agenda Sessions

  • Forecasting, Modeling and Valuation Strategies for Life Science Companies